🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

19+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 19 of 19 recruiting trials for “chronic-graft-versus-host-disease”

Phase 2RecruitingNCT07124078 ↗

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

👨‍⚕️ Incyte Medical Monitor, Incyte Corporation📍 38 sites📅 Started Mar 2026View details ↗
RecruitingNCT07127926 ↗

Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD

👨‍⚕️ Amin Alousi, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Feb 2026View details ↗
Phase 1RecruitingNCT07138196 ↗

A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease

🏥 Qurient Co., Ltd.📍 8 sites📅 Started Dec 2025View details ↗
Phase 2RecruitingNCT07116031 ↗

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

🏥 Sanofi📍 23 sites📅 Started Dec 2025View details ↗
Phase 1RecruitingNCT06233110 ↗

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

👨‍⚕️ Chenyu Lin, MD, Duke Health📍 1 site📅 Started Oct 2025View details ↗
Phase 2RecruitingNCT07011810 ↗

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

👨‍⚕️ Stephanie J. Lee, MD, MPH, Fred Hutch/University of Washington Cancer Consortium📍 3 sites📅 Started Aug 2025View details ↗
Phase 1, PHASE2RecruitingNCT07012304 ↗

Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy

🏥 Yujun DONG📍 1 site📅 Started Jun 2025View details ↗
Phase 1, PHASE2RecruitingNCT06843408 ↗

A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

👨‍⚕️ Incyte Medical Monitor, Incyte Corporation📍 9 sites📅 Started Jun 2025View details ↗
Phase 2RecruitingNCT06663722 ↗

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

👨‍⚕️ Trent P Wang, DO, University of Miami📍 1 site📅 Started May 2025View details ↗
Phase 3RecruitingNCT06585774 ↗

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

👨‍⚕️ Albert Assad, MD, Incyte Corporation📍 115 sites📅 Started Jan 2025View details ↗
Phase 2RecruitingNCT06660355 ↗

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

👨‍⚕️ Farhad Khimani, MD, Moffitt Cancer Center📍 4 sites📅 Started Dec 2024View details ↗
Phase 2RecruitingNCT06271616 ↗

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

👨‍⚕️ Mohamed A. Kharfan Dabaja, MD, MBA, Mayo Clinic📍 1 site📅 Started Dec 2024View details ↗
Phase 2RecruitingNCT06619561 ↗

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

👨‍⚕️ Clinical Team, Deciphera Pharmaceuticals, LLC📍 26 sites📅 Started Nov 2024View details ↗
Phase 2RecruitingNCT06388564 ↗

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

👨‍⚕️ Incyte Medical Monitor, Incyte Corporation📍 70 sites📅 Started Oct 2024View details ↗
NARecruitingNCT06247150 ↗

Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)

🏥 University Hospital, Bordeaux📍 1 site📅 Started May 2024View details ↗
Phase 2RecruitingNCT06300320 ↗

A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

🏥 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.📍 12 sites📅 Started May 2024View details ↗
Phase 2RecruitingNCT06046248 ↗

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

👨‍⚕️ Scott Solomon, MD, BMTGA/Northside Hospital📍 1 site📅 Started Jan 2024View details ↗
Phase 2RecruitingNCT05996627 ↗

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

👨‍⚕️ Stephanie Lee, MD, MPH, Fred Hutch/University of Washington Cancer Consortium📍 4 sites📅 Started Dec 2023View details ↗
Phase 2RecruitingNCT02918188 ↗

Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD

👨‍⚕️ Liren Qian, M.D., Navy General Hospital, Beijing📍 1 site📅 Started Jan 2016View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →